Omeprazole Market to Surpass US$ 4.1 Billion by 2026

“Omeprazole Market”
Omeprazole Market to Surpass US$ 4.1 Billion by 2026. Omeprazole Market ) was valued at US$ 2,668.4 million in 2017, and is projected to exhibit a CAGR of 5.2% over the forecast period (2018 – 2026)

Global Omeprazole Market, by Dosage Form (Capsule, Powder, and Tablet), by Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 2,668.4 million in 2017, and is projected to exhibit a CAGR of 5.2% over the forecast period (2018 – 2026), as highlighted in a new report published by Coherent Market Insights.

Launch of cost-effective generics by the market players to augment the market growth

The global omeprazole market is expected to witness significant growth over the forecast period attributed to increasing incidence of gastric ulcers caused due to H.pylori infection and Nonsteroidal Anti-Inflammatory Drugs (NSAID) use. According to the study by Deccan College of Medical Sciences, 2016, an estimated 95% of duodenal and 70% of gastric ulcers are attributed due to Helicobacter pylori. Furthermore, the study also stated that around 14-25% of gastric and duodenal ulcers are associated with NSAID use.

Get Sample PDF Of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2380

Furthermore, developers are focusing on approval and launch of cost-effective generic versions of omeprazole in order to enhance market sales. For instance, in July, 2017, Breckenridge Pharmaceutical, Inc. received the U.S. Food and Drug Administration (FDA) approval of abbreviated new drug application (ANDA) for Omeprazole delayed-release capsules. The drug will be manufactured and supplied by parent company- Laboratorios Dr. Esteve, S.A., Spain.

Browse 22 Market Data Tables and 24 Figures spread through 138 Pages and in-depth TOC on “Omeprazole Market”- Global Forecast to 2026, by Dosage Form (Capsule, Powder, and Tablet), by Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

To know the latest trends and insights prevalent in the omeprazole market, click the link below:

https://www.coherentmarketinsights.com/market-insight/omeprazole-market-2380

Gastroesophageal reflux disease (GERD) is a chronic digestive disorder where the stomach acid enters esophagus, causing inflammation. The condition results in a long-lasting and serious from of acid reflux. According to the National Institute of Diabetes and Digestive and Kidney Diseases, 2014, an estimated 15.1 to 30 percent of the U.S. population is diagnosed with GERD. Moreover, According to the Department of Gastroenterology, Cedars-Sinai Medical Center, 2014, over nine million primary care visits in the U.S. are attributed to GERD annually, making it the most common gastroenterology-related outpatient diagnosis disease in the country.

The market players are focused on developing treatment to offer heartburn relief by implementing innovative technologies. For instance, in April, 2018, Perrigo Company plc. and Dexcel Pharma Technologies, Ltd., launched Omeprazole delayed release orally disintegrating tablets (ODT) 20mg, with innovative MelTech melt-in-your-mouth technology for treating frequent heartburn. The innovative technology provides an affordable option in the OTC category.

Key Takeaways of the Omeprazole Market:

  • The global omeprazole market is expected to exhibit a CAGR of 5.2% over the forecast period, owing to increasing prevalence of peptic ulcer and acid related diseases and approval of generic versions by regulatory agencies. For instance, in 2016, Perrigo Company plc.received the U.S. FDA approval for omeprazole, thus launching a brand equivalent to Zegerid OTC capsules. Zegerid OTC is indicated for the treatment of frequent heartburn.
  • Among distribution channel, the online pharmacy segment is expected to holds a dominant position in the omeprazole market in 2026, owing to the higher amount of discount coupons granted for the generic and OTC omeprazole drugs
  • Some of the major players operating in the global omeprazole market include, Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc., Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave, 
#3200 
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Media Contact
Company Name: Coherent Market Insights
Contact Person: Mr. Shah
Email: Send Email
Phone: +1-206-701-6702
Address:1001 4th Ave, #3200
City: Seattle
State: Washington
Country: United States
Website: https://www.coherentmarketinsights.com/insight/buy-now/2380